DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)
DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)
DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
10<br />
Stop chasing asthma symptoms<br />
with a blue inhaler.<br />
Seek control instead. 1<br />
If your patients are using their blue reliever inhaler<br />
more than twice a week, chances are their asthma<br />
is not as good as it could be. 1 Prescribing Seretide<br />
can help free them from symptoms.* 2 Work with<br />
your patients to help control their asthma.<br />
Prescribe the purple inhaler – Seretide. 2,3<br />
*Patients treated with Seretide in the GOAL study achieved a median of 87% reliever free days and 72.5% symptom free days over 1 year.<br />
References: 1. Global Initiative for Asthma; Global Strategy for Asthma Management and Prevention. Updated 2009. 2. Woodcock AA et al. Prim Care Respir J. 2007;16(3):155-161. 3. Bateman ED et al.<br />
Am J Respir Crit Care Med. 2004;170:836-844<br />
Seretide ® (fluticasone propionate/salmeterol xinafoate inhaler 50/25, 125/25mcg per actuation and Accuhaler ® 100/50, 250/50mcg per actuation) is a fully funded medicine; Special Authority criteria apply. Seretide<br />
250/25mcg inhaler is a private purchase medicine; a prescription charge will apply. Maximum Daily Dose: MDI 2 puffs twice daily, Accuhaler 1 inhalation twice daily. Maintenance Dose: Titrate to lowest effective<br />
dose 1-2 times daily. Prescription Medicine for the treatment of reversible obstructive airway disease (ROAD) including asthma, and for the treatment of chronic obstructive pulmonary disease (COPD). Warnings and<br />
Precautions: Not for relief of acute symptoms. Do not discontinue abruptly. Use care when co-administering strong CYP3A4 inhibitors (e.g. ketoconazole) or in patients with pulmonary tuberculosis or thyrotoxicosis.<br />
Common side effects: hoarseness/dysphonia, throat irritation, headache, oral candidiasis and palpitations. Paradoxical bronchospasm may occur. Avoid beta-blockers if possible. Before prescribing Seretide, please review<br />
the Data Sheet at www.medsafe.govt.nz. Seretide and Accuhaler are registered trade marks of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland. TAPS DA4311IG/11FE/037
Change language